

Gelareh Farshid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3380115/publications.pdf>

Version: 2024-02-01

34
papers

1,046
citations

623574

14
h-index

434063

31
g-index

34
all docs

34
docs citations

34
times ranked

1422
citing authors

#	ARTICLE	IF	CITATIONS
1	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016, 68, 5-21.	1.6	329
2	Leiomyosarcoma of Somatic Soft Tissues. <i>American Journal of Surgical Pathology</i> , 2002, 26, 14-24.	2.1	128
3	Interobserver Variability by Pathologists in the Distinction Between Cellular Fibroadenomas and Phyllodes Tumors. <i>International Journal of Surgical Pathology</i> , 2014, 22, 695-698.	0.4	77
4	The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking. <i>Science Signaling</i> , 2015, 8, ra18.	1.6	57
5	Assessment of 142 Stellate Lesions With Imaging Features Suggestive of Radial Scar Discovered During Population-based Screening for Breast Cancer. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1626-1631.	2.1	50
6	A decision aid for predicting non-sentinel node involvement in women with breast cancer and at least one positive sentinel node. <i>Breast</i> , 2004, 13, 494-501.	0.9	44
7	Morphology of Breast Cancer as a Means of Triage of Patients for BRCA1 Genetic Testing. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1357-1366.	2.1	40
8	Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 165-177.	1.1	40
9	A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases. <i>Cancer Epidemiology</i> , 2019, 63, 101590.	0.8	31
10	Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 617-624.	1.1	29
11	Disparities in cancer stage at diagnosis and survival of Aboriginal and non-Aboriginal South Australians. <i>Cancer Epidemiology</i> , 2017, 48, 131-139.	0.8	21
12	XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. <i>Scientific Reports</i> , 2015, 5, 11465.	1.6	20
13	Molecular subtypes of screen-detected breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 191-199.	1.1	20
14	Disparities in breast screening, stage at diagnosis, cancer treatment and the subsequent risk of cancer death: a retrospective, matched cohort of aboriginal and non-aboriginal women with breast cancer. <i>BMC Health Services Research</i> , 2019, 19, 387.	0.9	18
15	HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program. <i>Pathology</i> , 2017, 49, 575-581.	0.3	15
16	Validation of the Multiplex Ligation-dependent Probe Amplification (MLPA) Technique for the Determination of HER2 Gene Amplification in Breast Cancer. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 11-17.	2.1	14
17	Atypical presentations of screen-detected DCIS Implications for pre-operative assessment and surgical intervention. <i>Breast</i> , 2007, 16, 161-171.	0.9	13
18	The clinical utility of assessment of the axilla in women with suspicious screen detected breast lesions in the post 20011 era. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 347-355.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Establishment of the Australian In Situ Hybridization Program for the Assessment of HER2 Amplification in Breast Cancer. <i>Diagnostic Molecular Pathology</i> , 2010, 19, 187-193.	2.1	11
20	Contemporary indications for diagnostic open biopsy in women assessed for screen-detected breast lesions: A ten-year, single institution series of 814 consecutive cases. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 49-58.	1.1	11
21	Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center. <i>Modern Pathology</i> , 2018, 31, 395-405.	2.9	11
22	ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. <i>Pathology</i> , 2019, 51, 345-348.	0.3	11
23	The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization. <i>Modern Pathology</i> , 2020, 33, 1783-1790.	2.9	11
24	Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. <i>Pathology</i> , 2016, 48, 535-542.	0.3	10
25	Performance Indices of Needle Biopsy Procedures for the Assessment of Screen Detected Abnormalities in Services Accredited by BreastScreen Australia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 15, 10665-10673.	0.5	5
26	Monitoring TNM stage of female breast cancer and survival across the South Australian population, with national and international TNM benchmarking: A population-based cohort study. <i>BMJ Open</i> , 2020, 10, e037069.	0.8	4
27	Female breast cancer treatment and survival in South Australia: Results from linked health data. <i>European Journal of Cancer Care</i> , 2021, 30, e13451.	0.7	3
28	Routine reporting of mammographic density from screening mammograms. <i>ANZ Journal of Surgery</i> , 2017, 87, 965-967.	0.3	2
29	Phosphaturic mesenchymal tumour: an interesting diagnostic and surgical case of tumour-induced osteomalacia. <i>ANZ Journal of Surgery</i> , 2020, 90, 1812-1814.	0.3	2
30	Investigating the breast cancer screeningâ€“treatmentâ€“mortality pathway of women diagnosed with invasive breast cancer: Results from linked health data. <i>European Journal of Cancer Care</i> , 2022, 31, e13539.	0.7	2
31	Multicentric myofibroblastic sarcoma. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013201666-bcr2013201666.	0.2	1
32	Surfer's bursa: a recurrent chest wall mass in dedicated surfers that may mimic a sarcoma. <i>Pathology</i> , 2021, 53, 550-552.	0.3	1
33	Change of blue ink margin colour to black in immunohistochemistry stained slides: a potential pitfall for pathology cancer margin assessment. <i>Pathology</i> , 2021, 53, 558-559.	0.3	1
34	Interobserver concordance in visual assessment of Ki67 immunohistochemistry in surgical excision specimens from patients with lymph node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 729-737.	1.1	1